Stocktoria
Dr. Reddy's Laboratories Limited DRREDDY.NS
IN · National Stock Exchange of India · XNSE · stock · Healthcare · website
Dr. Reddy's Laboratories Limited financials (annual)
Bars are annual figures from 2023 to 2026; red bars are negative (a loss or cash outflow).
| Metric | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue | ₹335.9B | ₹325.5B | ₹279.2B | ₹245.9B |
| Gross profit | ₹177.3B | ₹190.4B | ₹163.6B | ₹139.3B |
| R&D expense | ₹24.1B | ₹27.4B | ₹22.9B | ₹19.4B |
| SG&A expense | ₹106.8B | ₹93.9B | ₹77.2B | ₹68.0B |
| Operating income | ₹50.1B | ₹72.0B | ₹65.3B | ₹59.1B |
| Interest expense | ₹3.7B | ₹2.8B | ₹1.7B | ₹1.4B |
| Income tax | ₹12.4B | ₹19.5B | ₹16.2B | ₹15.3B |
| Net income | ₹42.9B | ₹56.5B | ₹55.7B | ₹45.1B |
| EPS (diluted) | ₹51.42 | ₹67.79 | ₹66.92 | ₹54.18 |
| Operating cash flow | ₹56.8B | ₹46.4B | ₹45.4B | ₹58.9B |
| Free cash flow | ₹18.3B | ₹12.0B | ₹18.0B | ₹40.0B |
| Cash & equivalents | ₹15.4B | ₹14.7B | ₹7.1B | ₹5.8B |
| Inventory | ₹76.5B | ₹71.1B | ₹63.6B | ₹48.7B |
| Total assets | ₹579.3B | ₹493.0B | ₹387.5B | ₹321.9B |
| Total liabilities | ₹198.9B | ₹155.8B | ₹107.0B | ₹90.9B |
| Shareholders' equity | ₹377.1B | ₹333.4B | ₹280.6B | ₹231.0B |
Growth · year-over-year · Revenue CAGR 11%
| Metric | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue growth | +3.2% | +16.6% | +13.5% | — |
| Net income growth | -24.2% | +1.5% | +23.6% | — |
| EPS growth | -24.1% | +1.3% | +23.5% | — |
| Free cash flow growth | +52.4% | -33.2% | -55.0% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · IN · as of 2026-03-31. Figures in INR. Facts plus Stocktoria's own computed scores — not investment advice.